First patient treated in the US-based prostate cancer imaging trial of Cu-64 SAR-bisPSMA
Sydney, Australia 21 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in the diagnostic US-based 64Cu SAR-bisPSMA trial for patients with biochemical recurrence (BCR) of prostate cancer. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent…